West Pharmaceutical Services, Inc. (WST) earnings on July 23, 2026

Before the market opens Q2 2026

More West Pharmaceutical Services, Inc. earnings

Prior outlook: Optimistic Outcome: Partial

The stock jumped as much as 9.65% during market review but couldn't hold those gains, closing down 0.82% on the day.

WST price around the earnings

355.48

Change: -0.8%

2026-07-23, 20:00 UTC

End of the measured window
352.75 366.16 379.58 393.00 358.41
Price series around the eventClosing price per minute from before the event to the end of the measured window.
July 23, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Partial

Thesis published
Results released

Exceptional earnings record (100% beat, +18.2% avg) with strong analyst coverage, but modest implied move.

Context analyzed before publication

Trend
Sharp decline from +68.6 to +32.8 over 2 days; optimistic but moderating into earnings.

Analysts

Evidence

Analyst consensus
Strong buy
Consensus average (1-5)
1.5
Analysts covering the stock
15
Average price target
385.33
Lowest price target
310
Highest price target
447
Upside to price target
7.5%
Quarterly earnings growth
54.6%
Revenue growth
21%
Forward EPS
9.62
Trailing EPS
7.45
Analyst moves in the last 60 days
7
  • Strong buy: 3
  • Buy: 11
  • Hold: 1
  • Sell: 0
  • Strong sell: 1
Strong buy
3
Buy
11
Hold
1
Sell
0
Strong sell
1
  • July 13, 2026 · BNP Paribas: Initiates coverage (Outperform)
  • July 9, 2026 · Morgan Stanley: Maintains rating (Equal-Weight → Equal-Weight)
  • July 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
  • July 2, 2026 · Keybanc: Maintains rating (Overweight → Overweight)
  • June 9, 2026 · Barclays: Upgrades rating (Equal-Weight → Overweight)
  • June 2, 2026 · Stephens & Co.: Reiterates rating (Overweight → Overweight)
  • May 29, 2026 · Morgan Stanley: Maintains rating (Equal-Weight → Equal-Weight)

News and sentiment

Evidence

Sentiment
Sentiment
Neutral
Mentions
0
News
Sources (5)

Technicals

Evidence

Average true range (ATR)
1.9%
Distance to 52-week high
-2.0%
14-day change (14d)
+1.5%
30-day change (30d)
+8.8%
30-day relative strength
+8.4%
SPY change (30d)
+0.4%
Nearest support
358.25
Nearest resistance
360.36
Volume accumulation ratio (14d / 46d)
0.83

Trends

Evidence

Average earnings surprise
+18.2%
  • April 23, 2026: actual EPS 2.13 vs estimate 1.68 (surprise +27.1%)
  • February 12, 2026: actual EPS 2.04 vs estimate 1.83 (surprise +11.5%)
  • October 23, 2025: actual EPS 1.96 vs estimate 1.71 (surprise +14.6%)
  • July 24, 2025: actual EPS 1.84 vs estimate 1.54 (surprise +19.7%)

Expected move

Implied move
+2.5%
Source
Options chain

Reactions over its last 20 earnings

Median move
7.5%
75th percentile move
14.2%
90th percentile move
16.1%
Up / down moves
8 / 12
Average up move
+11.4%
Average down move
-9.0%

Monitoring and close

What West Pharmaceutical Services, Inc. reported

Status
Finished
Actual EPS2.37
EPS estimate2.08
EPS surprise+13.9%
Revenue$872 million
Revenue estimate$839 million
Revenue surprise+4.0%

West Pharmaceutical beat Q2 2026 estimates, raised FY2026 guidance on strong GLP-1 and high-value products growth. Stock surged amid robust revenue and EPS performance.

Sources (16)

Pre-market second reading after the results

Verdict
Beat expectations

Heading into the open, the figures confirm the optimistic scenario. In the 1037 past cases with a similar move, the close held that direction 96% of the time.

How the stock reacted

Outcome
Partial
Consolidated
-0.8%
Max favorable move (MFE)
9.7%
Max adverse move (MAE)
1.6%